These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11521803)

  • 21. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.
    Berkman AM; Hildebrandt MAT; Landstrom AP
    Clin Genet; 2021 Aug; 100(2):132-143. PubMed ID: 33871046
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
    Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.
    Jones M; O'Gorman P; Kelly C; Mahon N; Fitzgibbon MC
    Ann Clin Biochem; 2017 Jan; 54(1):149-157. PubMed ID: 27170025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case report and review of the literature: the utilisation of a ventricular assist device as bridge to recovery for anthracycline-induced ventricular dysfunction.
    Krasnopero D; Asante-Korang A; Jacobs JP; Stapleton S; Carapellucci J; Dotson M; Stapleton G
    Cardiol Young; 2018 Mar; 28(3):471-475. PubMed ID: 29198224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
    Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
    Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
    Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
    Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
    Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
    Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for anthracycline-associated cardiotoxicity.
    Reinbolt RE; Patel R; Pan X; Timmers CD; Pilarski R; Shapiro CL; Lustberg MB
    Support Care Cancer; 2016 May; 24(5):2173-2180. PubMed ID: 26563179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
    Steinherz LJ; Steinherz PG; Tan C
    Med Pediatr Oncol; 1995 Jun; 24(6):352-61. PubMed ID: 7715541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subacute anthracycline cardiotoxicity.
    Hengel CL; Russell PA; Gould PA; Kaye DM
    Heart Lung Circ; 2006 Feb; 15(1):59-61. PubMed ID: 16473794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
    Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
    Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
    Kremer LC; van der Pal HJ; Offringa M; van Dalen EC; Voûte PA
    Ann Oncol; 2002 Jun; 13(6):819-29. PubMed ID: 12123328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to improve quality of life in patients with acute leukemia and comorbid ischemic heart disease treated with anthracycline-based induction chemotherapy.
    Skrypnyk I; Maslova G; Lymanets T; Gusachenko I
    Exp Oncol; 2019 Dec; 41(4):353-356. PubMed ID: 31868328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disclosing an In-Frame Deletion of the Titin Gene as the Possible Predisposing Factor of Anthracycline-Induced Cardiomyopathy: A Case Report.
    Chang YW; Weng HY; Tsai SF; Fan FS
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Usefulness of determining the blood levels of B-type natriuretic peptide in the evaluation of cardiotoxicity in children treated with anthracyclines].
    Jackowska T; Wasilewski R
    Med Wieku Rozwoj; 2006; 10(3 Pt 1):767-74. PubMed ID: 17317907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
    Armenian S; Bhatia S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():3-12. PubMed ID: 30231396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
    Minotti G; Cairo G; Monti E
    FASEB J; 1999 Feb; 13(2):199-212. PubMed ID: 9973309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthracycline and Peripartum Cardiomyopathies.
    Cowgill JA; Francis SA; Sawyer DB
    Circ Res; 2019 May; 124(11):1633-1646. PubMed ID: 31120822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.